In the ongoing phase I/II clinical trial conducted by the PersonGen Biotherapeutics (Suzhou) Co., Ltd., anti-MUC1 CAR-T cells are being used to treat advanced refractory solid tumours, including NSCLC (NCT02587689). Here, MUC1 is linked to non-small cell lung carcinoma.